Fake COVID-19 and Influenza Test Kits Detected on European Market

Summary – A batch of manipulated combined COVID-19 and influenza test units has been identified in Europe, prompting official warnings and recalls.,

Article –

Fake COVID-19 and Influenza Test Kits Detected on European Market

What Happened?

In early June 2024, health authorities across Europe uncovered a batch of manipulated combined test kits meant for detecting COVID-19 and influenza viruses. The batch, identified as FCO24090516, was confirmed as counterfeit by the manufacturer. This raises significant concerns about the accuracy and reliability of such diagnostic tools available in the European market.

Who Is Involved?

The counterfeit test kits were distributed throughout various European Union member states. The original manufacturer, whose identity remains confidential for privacy, officially declared that batch FCO24090516 is fake and was not produced under its quality control conditions. Efforts to trace and remove these counterfeit kits are being coordinated by European health agencies and the European Medicines Agency (EMA).

European Reactions

• The European Commission’s Directorate-General for Health and Food Safety (DG SANTE) urged vigilance among member states, requesting prompt reporting of any suspicious test kits.
• DG SANTE highlighted the public health risks posed by false negative or false positive results stemming from counterfeit products.
• The European Centre for Disease Prevention and Control (ECDC) stressed the need for strict quality assurance, especially in periods of heightened virus circulation.
• Several national health authorities have initiated recalls of the affected batch and are investigating the distribution scope and testing impact.
• Public health officials emphasized the importance of using authorized and reliable testing devices.

Immediate Consequences

The infiltration of fake combined COVID-19 and influenza test kits threatens disease surveillance and patient care by potentially causing misdiagnoses, delays in treatment, and hampering respiratory illness monitoring during peak seasons.

Economically, there are risks of losses for genuine manufacturers and distributors, alongside costs associated with recalls and replacements. Moreover, public confidence in diagnostic testing procedures could be seriously undermined.

What Comes Next?

1. The European Commission, EMA, and EU member states are set to strengthen border inspections and market surveillance to block counterfeit medical devices from entering and circulating within the market.
2. Further updates related to the ongoing investigation and remedial actions are expected in the upcoming weeks.
3. Healthcare providers and consumers are encouraged to verify the authenticity of test kits through official channels and report any irregularities without delay.

Stay tuned to Questiqa Europe for continuous regional updates and reports on this matter.

About The Author